MATCH-R trial is an ongoing prospective clinico-biological study, whose main objective is to understand mechanisms of acquired resistance to specific cancer therapies and guide to design new treatment strategies to overcome resistance. Patients (pts) in case of progressive disease are required to undergo a tumor biopsy (bx) to perform extensive molecular profiling (WES and RNAseq).
This study aims to describe the characteristics of the population, targeted treatment and molecular profile found through tumor bx for each type of solid tumor. We collected data from medical records and molecular profile reports from tissue bx that underwent NGS from December 2014 to December 2021 within the MATCH-R trial (NCT02517892), focusing on the molecular target group (MTG), which is the population that received target therapy prior and/or after MATCH-R bx with >1% of tumor cells (TC).
876 pts were enrolled of which 930 bx were obtained, (41 pts had more than one bx). 814 (87%) pts presented one bx with >1% viable TC. The percentage of TC was >30% among 568 bx; 11-30%: 211 bx, 1-10%: 77 bx; 0%: 72 bx. Within the MTG 269 pts were included; 174 pts (65%) were female with a median age of 57 (range 23-89). Most common cancer types were: lung [186, 69%], gastrointestinal [38, 14%], genitourinary [16, 6%], gynecological [10, 4%], endocrine [7, 3%] and breast [5, 22%]. The most frequently mutated/rearranged genes were EGFR (41%), FGFR 2-3 (15%), ALK (11%), BRAF (8%), KRAS (5%), ROS1 (4%), RET (3%), BRCA 1-2 (3%), MET (2.6%), HER2 (2%), NTKR (1.1%) and PIK3CA (0.7%). All pts received treatment for solid tumors with a median of 4 lines (range 1-13). The median number of target therapy lines received prior and after MATCH-R bx was 1 [1-6] and 1 [1-5] respectively. Median follow-up after MATCH-R bx was 10 months [2-87].
MATCH-R achieved an adequate tissue quality, at progressive disease, to perform extensive molecular profile. This study will provide valuable information that, through translational research, will allow us to understand the possible resistance mechanisms for the different treatments. Further updates will be provided.
The authors.
Has not received any funding.
C. Baldini: Non-Financial Interests, Personal, Other: AstraZeneca, Bayer, BMS, Boehringer Ingelheim, GSK, MedImmune, Merck, NH TherAGuiX, Pfizer, Roche; Financial Interests, Personal, Other: GSK, BMS, AZ, Amgen, Sanofi, MSD travel accommodation; Non-Financial Interests, Personal, Principal Investigator: Principal/sub-Investigator of Clinical Trials for AbbVie, Adaptimmune, Adlai Nortye USA Inc., Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Arno Therapeutics, Astex Pharmaceuticals, AstraZeneca Ab, Aveo, Basilea Pharmaceutica International L; Other, Personal, Funding: BMS Fundation; Other, Personal, Research Grant: from AstraZeneca, BMS, Boehringer Ingelheim, GSK, INCA, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi. J. Soria: Financial Interests, Personal, Other: AstraZeneca and is now employed by Amgen; owns stock in AstraZeneca, Gritstone Bio, Relay Therapeutics; and serves on the Board of Directors for Hookipa Pharmaceuticals outside the submitted work. Giuseppe Curigliano reports a grant from Merck; Consul, Pfizer, Novartis, Seattle Genetics, Daiichi Sankyo. Y. Loriot: Financial Interests, Personal, Other: Astellas, Other, Personal, lectures, advisory boards AstraZeneca, Other, Personal, lectures, advisory boards BMS, Other, Personal, lectures, advisory boards Gilead, Advisory Board, Personal Janssen, Other, Personal, lectures, advisory boards Merck KGaA, A; Non-Financial Interests, Personal, Other: Incyte, Local PI, Institutional, Financial interest Janssen, Coordinating PI, Institutional, Financial interest Janssen, Steering Committee Member, Institutional, Financial interest Janssen, Local PI, Institutional, Financial interest Janssen, Research Gr. F. André: Financial Interests, Personal, Funding: Roche, AstraZeneca, Daiichi Sankyo, Pfizer, Novartis, Lilly; Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, Daiichi Sankyo, Pfizer, Novartis, Lilly; Financial Interests, Personal, Research Grant: Roche, AstraZeneca, Daiichi Sankyo, Pfizer, Novartis, Lilly. B. Besse: Financial Interests, Personal, Other: Sponsored Research at Gustave Roussy Cancer Center 4D Pharma, AbbVie, Amgen, Aptitude Health, AstraZeneca, BeiGene, Blueprint Medicines, Boehringer Ingelheim, Celgene, Cergentis, Chugai Pharmaceutical, Cristal Therapeutics, Daiichi Sankyo, Eli Lilly, Eisai. S. Ponce: Financial Interests, Personal, Other: Roche, MSD, AstraZeneca, Bristol Myers Squibb, PharmaMar, Boehringer Ingelheim, BMS. Expert testimony: Roche, MSD, AstraZeneca, Bristol Myers Squibb, PharmaMar, Boehringer Ingelheim, BMS. Travel, accommodations, expenses: MSD, Roche, BMS, AstraZeneca, Ph, RSD Pharma; Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb. All other authors have declared no conflicts of interest.